[{"orgOrder":0,"company":"Medison Pharma","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Partnership","leadProduct":"Patisiran","moa":"mTTR mRNA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medison Pharma \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2023","type":"Expanded Collaboration","leadProduct":"Givosiran Sodium","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medison Pharma \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Ripretinib","moa":"c-KIT receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medison Pharma \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Immunocore","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2022","type":"Agreement","leadProduct":"Tebentafusp","moa":"GP100","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medison Pharma \/ Immunocore","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Immunocore"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Albireo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Odevixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medison Pharma \/ Albireo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Albireo Pharma"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Cemiplimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medison Pharma \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Hormone","year":"2021","type":"Agreement","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medison Pharma \/ Amryt Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Amryt Pharma"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Zanubrutinib","moa":"BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medison Pharma \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Medison Pharma \/ BeiGene"}]

Find Clinical Drug Pipeline Developments & Deals by Medison Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Medison will commercialize Libtayo (cemiplimab), an anti-PD-1 monoclonal antibody, in select European and global markets under a new agreement.

                          Product Name : Libtayo

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          August 01, 2024

                          Lead Product(s) : Cemiplimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Alnylam's collaboration with Medison leverages Medison’s multi-regional platform to make RNAi therapeutics like ONPATTRO, GIVLAARI, and OXLUMO available in LATAM, APAC, and additional global markets.

                          Product Name : Onpattro

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          April 30, 2024

                          Lead Product(s) : Patisiran

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Alnylam Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The new agreement will allow Alnylam to utilize Medison's unique multi-regional platform to ensure that Alnylam's innovative RNAi therapeutics, such as ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran) are made available across additiona...

                          Product Name : Givlaari

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          September 03, 2023

                          Lead Product(s) : Givosiran Sodium

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Alnylam Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank

                          04

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Under the agreement with Albireo, Medison aims to commercialize Odevixibat in Canada and Israel, for the treatment of patients with cholestatic liver diseases. Odevixibat is approved in Europe as Bylvay® for the treatment of progressive familial intrahe...

                          Product Name : Bylvay

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 16, 2022

                          Lead Product(s) : Odevixibat

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Approved FDF

                          Sponsor : Albireo Pharma

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          05

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The multi-territorial agreement to help seek regulatory authorization and commercialize Immunocore's KIMMTRAK® (tebentafusp -tebn) for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma that affects the ey...

                          Product Name : Kimmtrak

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          May 23, 2022

                          Lead Product(s) : Tebentafusp

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Immunocore

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : This agreement completes the multi-regional distribution agreements with Medison, announced in February, to distribute Myalept® (metreleptin) and Lojuxta® (lomitapide) in Israel, and Juxtapid® (lomitapide) in Canada.

                          Product Name : Myalepta

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          August 03, 2021

                          Lead Product(s) : Metreleptin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Amryt Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          07

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Deciphera Pharmaceuticals will distribution and commercialize QINLOCK, a switch-control tyrosine kinase inhibitor, in Canada and Israel for the treatment of fourth-line gastrointestinal stromal tumor (GIST).

                          Product Name : Qinlock

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 11, 2020

                          Lead Product(s) : Ripretinib

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Deciphera Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          08

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : Medison will commercialize BeiGene’s BTK inhibitor BRUKINSA™ (zanubrutinib) in Israel and the acceptance of a new drug application (NDA) in Israel for BRUKINSA for the treatment of patients with mantle cell lymphoma (MCL) who have received at least o...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 21, 2020

                          Lead Product(s) : Zanubrutinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : BeiGene

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank